Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
Membranous NECTIN-4 Expression Often Decreases During UC Metastases
Zachary Bessette
Advanced Urothelial Carcinoma
|
January 3, 2023
Membranous NECTIN-4 expression is frequently decreased or absent altogether in metastatic urothelial carcinoma tissue.
Read More
5-Year Follow-up Results of Pembrolizumab for Metastatic Urothelial Carcinoma
Emily Menendez
Advanced Urothelial Carcinoma
|
December 29, 2022
After five years follow-up, new results show the durability of response to pembrolizumab for metastatic urothelial carcinoma.
Read More
Case Study: HER2-Targeting Drug Plus Pembrolizumab for Third-Line Metastatic UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
December 12, 2022
A newly published case report may signify a promising novel antitumor strategy in locally advanced or metastatic UC.
Read More
Impact of Immune Checkpoint Inhibitors on Advanced Urothelial Carcinoma
Cecilia Brown
Advanced Urothelial Carcinoma
|
November 10, 2022
Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer.
View More
Extra Chemo Cycles Unlikely to Shrink Tumors in Advanced Urothelial Carcinoma
Cecilia Brown
Advanced Urothelial Carcinoma
|
November 10, 2022
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Read More
Longer OS With Enfortumab Vedotin Than Chemo in Advanced Urothelial Carcinoma
Cecilia Brown
Advanced Urothelial Carcinoma
|
November 10, 2022
Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma.
Read More
No First-line Therapy in Most Patients With Advanced Bladder Cancer
Cecilia Brown
Advanced Urothelial Carcinoma
|
November 10, 2022
Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy.
Read More
Targeted Therapy Provided Equivalent Outcomes to Chemotherapy in FGFR-Altered Urothelial Carcinoma
Leah Lawrence
Advanced Urothelial Carcinoma
|
October 18, 2022
FGFR-directed therapy had similar efficacy to chemotherapy in treating advanced or metastatic urothelial carcinoma.
Read More
Study Ranks Metastatic Urothelial Carcinoma Treatments
Cecilia Brown
Advanced Urothelial Carcinoma
|
October 14, 2022
Enfortumab vedotin ranks first in efficacy among 6 treatments for metastatic urothelial cancer.
Read More
Treatment Options for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
Cecilia Brown
Advanced Urothelial Carcinoma
|
October 14, 2022
Shilpa Gupta, MD, discusses treatments for cisplatin-ineligible patients with advanced bladder cancer.
View More
Higher Progression Risk in Women With Advanced Urothelial Carcinoma
Cecilia Brown
Advanced Urothelial Carcinoma
|
October 14, 2022
Women with advanced urothelial carcinoma have a significantly greater risk of progression after chemotherapy than men.
Read More
Lymphovascular Invasion in Upper Tract Urothelial Carcinoma Predicts Risk
Cecilia Brown
Advanced Urothelial Carcinoma
|
October 14, 2022
Lymphovascular invasion in upper tract urothelial carcinoma puts patients at higher risk for recurrence and mortality.
Read More
Albumin-Globulin Ratio Predicts Bladder Cancer Survival
Cecilia Brown
Advanced Urothelial Carcinoma
|
September 22, 2022
The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.
Read More
Study IDs Top Reason for Lack of Treatment in Patients With Bladder Cancer
Cecilia Brown
Advanced Urothelial Carcinoma
|
September 22, 2022
Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.
Read More
Applying Recent Developments in Targeted Molecular Therapeutics for Advanced Bladder Cancer
Cecilia Brown
Advanced Urothelial Carcinoma
|
September 22, 2022
Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.
View More
A "Promising Combination" for Cisplatin-Ineligible Patients With Bladder Cancer
Cecilia Brown
Advanced Urothelial Carcinoma
|
September 22, 2022
Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.
Read More
Neoadjuvant Radio-Immunotherapy Safe Option for Locally Advanced Bladder Cancer
Leah Lawrence
ESMO 2022
|
September 16, 2022
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Read More
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
GU Oncology Now Editors
Advanced Urothelial Carcinoma
|
June 3, 2022
...
Read More
The LINC01929/miR-6875-5p/ADAMTS12 Axis in the ceRNA Network Regulates the Development of Advanced Bladder Cancer
GU Oncology Now Editors
Advanced Urothelial Carcinoma
|
June 1, 2022
...
Read More
Survival after Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum-based Chemotherapy for Locally Advanced (Stage III) Urothelial Cancer
GU Oncology Now Editors
Advanced Urothelial Carcinoma
|
May 23, 2022
...
Read More
Load More
Advertisement
Advertisement
Advertisement